Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...